These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 24382005)
21. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Ho PP; Steinman L Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456 [TBL] [Abstract][Full Text] [Related]
22. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor. Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917 [TBL] [Abstract][Full Text] [Related]
24. Management of cholestatic disease in 2017. de Vries E; Beuers U Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628 [TBL] [Abstract][Full Text] [Related]
25. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348 [TBL] [Abstract][Full Text] [Related]
26. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Poupon R Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891 [TBL] [Abstract][Full Text] [Related]
28. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Gitto S; Guarneri V; Sartini A; Andreone P Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798 [TBL] [Abstract][Full Text] [Related]
29. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638 [TBL] [Abstract][Full Text] [Related]
30. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596 [TBL] [Abstract][Full Text] [Related]
31. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Fiorucci S; Di Giorgio C; Distrutti E Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552 [TBL] [Abstract][Full Text] [Related]
32. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472 [TBL] [Abstract][Full Text] [Related]
33. Current Treatment Options for Primary Biliary Cholangitis. Wong KA; Bahar R; Liu CH; Bowlus CL Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848 [TBL] [Abstract][Full Text] [Related]